Top

Breast Cancer Research and Treatment

Published in:

Open Access 01-05-2017 | Preclinical study

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data

Authors: Amila Orucevic, John L. Bell, Alison P. McNabb, Robert E. Heidel

Published in: Breast Cancer Research and Treatment | Issue 1/2017

Abstract

Purpose

Oncotype DX (ODX) recurrence score (RS) breast cancer (BC) assay is costly, and performed in only ~1/3 of estrogen receptor (ER)-positive BC patients in the USA. We have now developed a user-friendly nomogram surrogate prediction model for ODX based on a large dataset from the National Cancer Data Base (NCDB) to assist in selecting patients for which further ODX testing may not be necessary and as a surrogate for patients for which ODX testing is not affordable or available.

Methods

Six clinicopathologic variables of 27,719 ODX-tested ER+/HER2−/lymph node-negative patients with 6–50 mm tumor size captured by the NCDB from 2010 to 2012 were assessed with logistic regression to predict high-risk or low-risk ODXRS test results with TAILORx-trial and commercial cut-off values; 12,763 ODX-tested patients in 2013 were used for external validation. The predictive accuracy of the regression model was yielded using a Receiver Operator Characteristic analysis. Model fit was analyzed by plotting the predicted probabilities against the actual probabilities. A user-friendly calculator version of nomograms is available online at the University of Tennessee Medical Center website (Knoxville, TN).

Results

Grade and progesterone receptor status were the highest predictors of both low-risk and high-risk ODXRS, followed by age, tumor size, histologic tumor type and lymph-vascular invasion (C-indexes-.0.85 vs. 0.88 for TAILORx-trial vs. commercial cut-off values, respectively).

Conclusion

This is the first study of this scale showing confidently that clinicopathologic variables can be used for prediction of low-risk or high-risk ODXRS using our nomogram models. These novel nomograms will be useful tools to help physicians and patients decide whether further ODX testing is necessary and are excellent surrogates for patients for which ODX testing is not affordable or available.

Available only for authorised users

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. doi:10.1056/NEJMoa041588 CrossRefPubMed

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734. doi:10.1200/jco.2005.04.7985 CrossRefPubMed

Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF (2016) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(10):1134–1150. doi:10.1200/jco.2015.65.2289 CrossRefPubMedPubMedCentral

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R (2015) Breast cancer, version 1.2016. J Natl Compr Canc Netw 13(12):1475–1485PubMed

Henry NL, Somerfield MR, Abramson VG, Allison KH, Anders CK, Chingos DT, Hurria A, Openshaw TH, Krop IE (2016) Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. J Clin Oncol 34(19):2303–2311. doi:10.1200/jco.2015.65.8609 CrossRefPubMed

Orucevic A, Heidel RE, Bell JL (2016) Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis. Breast Cancer Res Treat 157(3):427–435. doi:10.1007/s10549-016-3833-9 CrossRefPubMedPubMedCentral

Albanell J, Svedman C, Gligorov J, Holt SD, Bertelli G, Blohmer JU, Rouzier R, Lluch A, Eiermann W (2016) Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative early-stage breast cancer. Eur J Cancer (Oxf Eng 1990) 66:104–113. doi:10.1016/j.ejca.2016.06.027 CrossRef

Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Carey LA, Troester MA, Wheeler SB (2016) Racial variation in the uptake of oncotype DX testing for early-stage breast cancer. J Clin Oncol 34(2):130–138. doi:10.1200/jco.2015.63.2489 CrossRefPubMed

Guth AA, Fineberg S, Fei K, Franco R, Bickell NA (2013) Utilization of oncotype DX in an Inner city population: race or place? Int J Breast Cancer 2013:653805. doi:10.1155/2013/653805 CrossRefPubMedPubMedCentral

10.

Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, Hearn S, Zelnak A, Styblo T, O’Regan RM (2012) 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer 118(3):788–796. doi:10.1002/cncr.26180 CrossRefPubMed

11.

Gage MM, Rosman M, Mylander WC, Giblin E, Kim HS, Cope L, Umbricht C, Wolff AC, Tafra L (2015) A validated model for identifying patients unlikely to benefit from the 21-gene recurrence score assay. Clin Breast Cancer 15(6):467–472. doi:10.1016/j.clbc.2015.04.006 CrossRefPubMedPubMedCentral

12.

Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, Bhargava R (2013) Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol 26(5):658–664. doi:10.1038/modpathol.2013.36 CrossRefPubMedPubMedCentral

13.

Ingoldsby H, Webber M, Wall D, Scarrott C, Newell J, Callagy G (2013) Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis. Breast (Edinb Scotl) 22(5):879–886. doi:10.1016/j.breast.2013.04.008 CrossRef

14.

Chaudhary LN, Jawa Z, Szabo A, Visotcky A, Chitambar CR (2016) Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score. Hematol/Oncol Stem Cell Therapy 9(2):48–54. doi:10.1016/j.hemonc.2015.12.001 CrossRef

15.

Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller DV, Armstrong DK, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC, Cope L (2016) Optimizing the use of gene expression profiling in early-stage breast cancer. J Clin Oncol 34(36):4390–4397CrossRefPubMed

16.

CAP (2014) Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-breast-biomarker-template-14.pdf. Accessed 26 Dec 2016

17.

Iasonos A, Schrag D, Raj GV, Panageas KS (2008) How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26(8):1364–1370. doi:10.1200/jco.2007.12.9791 CrossRefPubMed

18.

Cadoo KA, Fornier MN, Morris PG (2013) Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Quart J Nucl Med Mol Imaging 57(4):312–321

19.

R Core Team (2016) R: A language and environment for statistical computing. R Foundation for Statistical Computing. https://www.R-project.org/.2017

20.

Harrell FEJ (2017) rms: regression modeling strategies. http://CRAN.R-project.org/package=rms

21.

Harrell F (2015) Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis, 2nd edn. Springer, New YorkCrossRef

22.

Breastcancer.org Oncotype DX Test. http://www.breastcancer.org/symptoms/testing/types/oncotype_dx. Accessed 1/2/2017 2017

23.

Geradts J, Bean SM, Bentley RC, Barry WT (2010) The Oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 28(9):969–977. doi:10.3109/07357907.2010.512600 CrossRefPubMed

24.

Tang P, Wang J, Hicks DG, Wang X, Schiffhauer L, McMahon L, Yang Q, Shayne M, Huston A, Skinner KA, Griggs J, Lyman G (2010) A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest 28(9):978–982. doi:10.3109/07357907.2010.496754 CrossRefPubMed

25.

Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM (2012) Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat 131(2):413–424. doi:10.1007/s10549-011-1416-3 CrossRefPubMed

26.

Mattes MD, Mann JM, Ashamalla H, Tejwani A (2013) Routine histopathologic characteristics can predict oncotype DX(TM) recurrence score in subsets of breast cancer patients. Cancer Invest 31(9):604–606. doi:10.3109/07357907.2013.849725 CrossRefPubMed

27.

Turner BM, Skinner KA, Tang P, Jackson MC, Soukiazian N, Shayne M, Huston A, Ling M, Hicks DG (2015) Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Mod Pathol 28(7):921–931. doi:10.1038/modpathol.2015.50 CrossRefPubMed

28.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014. doi:10.1056/NEJMoa1510764 CrossRefPubMedPubMedCentral

29.

AJCC (2016) AJCC cancer staging manual, 8th edn. Springer, Chicago

30.

Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22(3):207–219CrossRefPubMed

31.

Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56(4):489–492CrossRefPubMedPubMedCentral

32.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology 22(8):1736–1747. doi:10.1093/annonc/mdr304 CrossRefPubMedPubMedCentral

33.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. doi:10.1200/JCO.2009.25.6529 CrossRefPubMedPubMedCentral

Title: Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
Authors: Amila Orucevic
John L. Bell
Alison P. McNabb
Robert E. Heidel
Publication date: 01-05-2017
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4170-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

A single-institution experience of salvage therapy for patients with early and locally advanced breast cancer who progress during neoadjuvant chemotherapy

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer

Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease

Retrospective review of genomic testing in breast cancer: Does it improve outcome?

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients

Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology

Keynote webinar | Spotlight on antibody–drug conjugates in cancer